Search

everythinglearnresearchcommunity

for

Search:↓

The user switched from finasteride and topical minoxidil to dutasteride, oral minoxidil, and topical minoxidil for 8 months, resulting in hair regrowth. Some users suggest dropping the topical minoxidil.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation humorously acknowledges the role of mice in testing Minoxidil for hair loss while also discussing the ethics of animal testing. Some users argue against animal testing, citing cruelty, while others defend its necessity for medical advancements.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

The user experienced significant hair regrowth by returning to a regimen of 1mg oral finasteride daily and daily topical minoxidil after previously reducing their doses. They also emphasize maintaining energy and health through diet, exercise, and supplements.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

A 26-year-old male started minoxidil treatment for male-pattern baldness and saw significant regrowth in three months. He is considering finasteride but is hesitant due to potential side effects.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

Someone's two-month progress using oral minoxidil (2.5mg ED) to treat hair loss, which has resulted in thicker eyebrows and eyelashes but no scalp changes or shedding.

A 39-year-old user experienced hair regrowth using oral dutasteride, oral minoxidil, dermastamping, and Nizoral shampoo after switching from finasteride and topical minoxidil. They are hopeful for significant improvement in their receding hairline.

The user experienced hair regrowth using finasteride and topical minoxidil, with consistent application and lifestyle changes like using cold water and exercising. They noted initial shedding when restarting minoxidil but saw positive results over six months.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.

The user is 3 months into using dutasteride and oral minoxidil after switching from finasteride, noticing potential regrowth with small hairs at the temples. They take 2.5mg oral minoxidil and 0.5mg dutasteride daily, with some eyelash and eyebrow growth observed.

A man in his late twenties switched from finasteride to dutasteride for hair loss and is sharing his 3-month progress, noting increased shedding but no side effects. Some responders think the treatment is working.

Mango oil may inhibit DKK1 and DHT, potentially aiding hair growth by activating the Wnt signaling pathway. A user plans to test mango leaves juice and other Ayurvedic products for hair regrowth.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

The user experienced significant hair regrowth in 5 weeks using Minoxidil, Finasteride, Dutasteride, biotin, collagen, derma stamping, and a mixture of oils, leading others to label them a "hyper responder." Some users advised caution with microneedling frequency to avoid potential scarring.

Minoxidil is extremely toxic to cats, even in small amounts, and can be fatal. Switching to oral minoxidil is safer for cat owners, but precautions should still be taken to prevent exposure.

A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

The user experienced significant hair regrowth using 5mg oral Minoxidil and 0.5mg oral Dutasteride daily, with no side effects except increased body and eyebrow hair. They are concerned about progress plateauing but have not experienced shedding.

The user experienced severe hair shedding from RU58841 and recovered by stopping its use and starting treatments including Minoxidil, Rosemary Verbenone, Stemoxydine, Aminexil, copper peptide serum, and specific shampoos. They also consistently used oral Finasteride and plan to try Minoxidil 10%.

The user experienced significant hair regrowth using finasteride and minoxidil. They plan to switch to dutasteride for its potency after confirming their body's tolerance to DHT blockers.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.